250 related articles for article (PubMed ID: 31039332)
1. Current perspectives on established and novel therapies for pathological neovascularization in retinal disease.
Campbell M; Doyle SL
Biochem Pharmacol; 2019 Jun; 164():321-325. PubMed ID: 31039332
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of APE1/Ref-1 for Neovascular Eye Diseases: From Biology to Therapy.
Hartman GD; Lambert-Cheatham NA; Kelley MR; Corson TW
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638620
[TBL] [Abstract][Full Text] [Related]
3. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review.
Yang S; Zhao J; Sun X
Drug Des Devel Ther; 2016; 10():1857-67. PubMed ID: 27330279
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy.
Bandello F; Corvi F; La Spina C; Benatti L; Querques L; Capuano V; Naysan J; Chen X; Sarraf D; Parodi MB; Souied E; Freund KB; Querques G
Br J Ophthalmol; 2016 Dec; 100(12):1611-1616. PubMed ID: 26951773
[TBL] [Abstract][Full Text] [Related]
5. An update on the pharmacotherapy of neovascular age-related macular degeneration.
Freund KB; Mrejen S; Gallego-Pinazo R
Expert Opin Pharmacother; 2013 Jun; 14(8):1017-28. PubMed ID: 23560774
[TBL] [Abstract][Full Text] [Related]
6. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV.
Wecker T; Ehlken C; Bühler A; Lange C; Agostini H; Böhringer D; Stahl A
Br J Ophthalmol; 2017 Mar; 101(3):353-359. PubMed ID: 27215744
[TBL] [Abstract][Full Text] [Related]
7. FGF21 Administration Suppresses Retinal and Choroidal Neovascularization in Mice.
Fu Z; Gong Y; Liegl R; Wang Z; Liu CH; Meng SS; Burnim SB; Saba NJ; Fredrick TW; Morss PC; Hellstrom A; Talukdar S; Smith LE
Cell Rep; 2017 Feb; 18(7):1606-1613. PubMed ID: 28199833
[TBL] [Abstract][Full Text] [Related]
8. The VEGF paradox: Does diabetic retinopathy protect from age related macular degeneration?
Saravia M; Zeman L; Ingolotti M; Schlaen A
Med Hypotheses; 2017 Nov; 109():156-161. PubMed ID: 29150277
[TBL] [Abstract][Full Text] [Related]
9. Role of vascular endothelial growth factor in ocular angiogenesis.
Shams N; Ianchulev T
Ophthalmol Clin North Am; 2006 Sep; 19(3):335-44. PubMed ID: 16935208
[TBL] [Abstract][Full Text] [Related]
10. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration.
Eyetech Study Group
Retina; 2002 Apr; 22(2):143-52. PubMed ID: 11927845
[TBL] [Abstract][Full Text] [Related]
11. Combined VEGF and PDGF inhibition for neovascular AMD: anti-angiogenic properties of axitinib on human endothelial cells and pericytes in vitro.
Siedlecki J; Wertheimer C; Wolf A; Liegl R; Priglinger C; Priglinger S; Eibl-Lindner K
Graefes Arch Clin Exp Ophthalmol; 2017 May; 255(5):963-972. PubMed ID: 28161830
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment.
El-Mollayess GM; Noureddine BN; Bashshur ZF
Semin Ophthalmol; 2011 May; 26(3):69-76. PubMed ID: 21609219
[TBL] [Abstract][Full Text] [Related]
13. [What can anti-VEGF therapy achieve in clinical routine? : Effectiveness of anti-VEGF therapy in patients with macular diseases in clinical routine on 1492 eyes in Austria].
Wiesinger K; Reinelt P; Ennemoser A; Edelmayr M; Schönherr U
Ophthalmologe; 2017 Jul; 114(7):639-645. PubMed ID: 27815675
[TBL] [Abstract][Full Text] [Related]
14. Ophthalmic Application of Anti-VEGF Therapy.
Lai TYY; Cheung CMG; Mieler WF
Asia Pac J Ophthalmol (Phila); 2017; 6(6):479-480. PubMed ID: 29204994
[No Abstract] [Full Text] [Related]
15. Therapeutic Efficacy of a Novel Acetylated Tetrapeptide in Animal Models of Age-Related Macular Degeneration.
Koo HC; Baek YY; Choi JS; Kim YM; Sung B; Kim MJ; Kim JG; You JC
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33918777
[TBL] [Abstract][Full Text] [Related]
16. A Review: Proteomics in Retinal Artery Occlusion, Retinal Vein Occlusion, Diabetic Retinopathy and Acquired Macular Disorders.
Cehofski LJ; Honoré B; Vorum H
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28452939
[TBL] [Abstract][Full Text] [Related]
17. Systemic adverse drug reactions secondary to anti-VEGF intravitreal injection in patients with neovascular age-related macular degeneration.
Semeraro F; Morescalchi F; Parmeggiani F; Arcidiacono B; Costagliola C
Curr Vasc Pharmacol; 2011 Sep; 9(5):629-46. PubMed ID: 21470108
[TBL] [Abstract][Full Text] [Related]
18. Subfoveal choroidal thickness changes after intravitreal bevacizumab injection for neovascular age-related macular degeneration and diabetic macular edema.
Ünlü C; Erdogan G; Gunay BO; Kardes E; Akcay BI; Ergin A
Int Ophthalmol; 2017 Feb; 37(1):147-158. PubMed ID: 27154721
[TBL] [Abstract][Full Text] [Related]
19. An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration.
Feng L; Hu JH; Chen J; Xie X
J Zhejiang Univ Sci B; 2018 Apr.; 19(4):327-332. PubMed ID: 29616508
[TBL] [Abstract][Full Text] [Related]
20. The role of placental growth factor (PlGF) and its receptor system in retinal vascular diseases.
Van Bergen T; Etienne I; Cunningham F; Moons L; Schlingemann RO; Feyen JHM; Stitt AW
Prog Retin Eye Res; 2019 Mar; 69():116-136. PubMed ID: 30385175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
